Zen­tal­is shakes up PhI­II plans in ovar­i­an can­cer; Halozyme's deal with Acu­men; Ko­r­ro's $117M pri­vate place­ment

Zen­tal­is Phar­ma shakes up plans for Phase III in ovar­i­an can­cer: Zen­tal­is an­nounced Mon­day that it is no longer plan­ning to test its lead can­di­date, azenosert­ib, in com­bi­na­tion with chemother­a­py in sec­ond-line plat­inum-sen­si­tive ovar­i­an can­cer (PSOC) pa­tients. The Phase III study was ex­pect­ed to start in the first quar­ter of next year. In­stead, the com­pa­ny plans to test the wee1 in­hibitor as a first-line main­te­nance treat­ment for PSOC, push­ing back the time­line for be­gin­ning a Phase III tri­al in­to 2025. Zen­tal­is al­so shared up­dat­ed re­sults from a Phase I study in plat­inum-re­sis­tant ovar­i­an can­cer. The biotech is cur­rent­ly run­ning a Phase II tri­al for which it plans to share topline da­ta in 2025. Zen­tal­is {ZNTL} shares fell over 20% af­ter mar­kets opened Mon­day. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER